Sekmek, SerhatBolek, HaticeKuzu, Omer FarukCamoz, Elif SertesenSim, SaadetKarakas, HilalUrun, Yuksel2025-07-252025-07-2520251750-743X1750-7448https://doi.org/10.1080/1750743X.2025.2527019https://hdl.handle.net/20.500.14365/6292Bolek, Hatice/0000-0001-8659-7327;AimsTo investigate the effect of uric acid level on prognosis in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.Materials and methodsThis retrospective study utilized data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC), which is a multicenter registry encompassing 13 cancer centers across T & uuml;rkiye.Results and conclusionsA total of 189 patients were included in the study. The median age was 61 years in all cohort. Univariable analyses revealed longer TTF (17.87 vs. 6.57 months, p = 0.014) and OS (52.01 vs. 25.36, p = 0.032) in the uric acid-high (UAH) group than in the uric acid-low (UAL) group. In multivariable analyses, low uric acid level emerged as an independent risk factor for OS (hazard ratio (HR): 1.82, 95% confidence interval (CI): 1.09-3.05; p = 0.022), whereas no significant association was observed with TTF (HR: 1.24, 95% CI: 0.72-2.13; p = 0.431). While uric acid levels were a significant independent prognostic factor for OS, no association was found with TTF. Our findings underscore the prognostic importance of uric acid in mRCC, suggesting its potential role as a biomarker for risk stratificationeninfo:eu-repo/semantics/closedAccessImmunotherapyKidney CancerPrognosisBiomarkerRenal Cell CarcinomaSurvivalNivolumabArticle10.1080/1750743X.2025.25270192-s2.0-105009904702